You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial
|
|---|---|
| Published in |
Gastric Cancer, February 2018
|
| DOI | 10.1007/s10120-018-0815-0 |
| Pubmed ID | |
| Authors |
Kazuhiro Nishikawa, Akira Tsuburaya, Takaki Yoshikawa, Masazumi Takahashi, Kazuaki Tanabe, Kensei Yamaguchi, Shigefumi Yoshino, Tsutomu Namikawa, Toru Aoyama, Yasushi Rino, Junji Kawada, Akihito Tsuji, Koichi Taira, Yutaka Kimura, Yasuhiro Kodera, Yoshinori Hirashima, Hiroshi Yabusaki, Naoki Hirabayashi, Kazumasa Fujitani, Yumi Miyashita, Satoshi Morita, Junichi Sakamoto |
| Abstract |
In Japan, standard regimens for advanced gastric cancer (AGC) include S-1 chemotherapy. The standard treatment for early relapse after adjuvant chemotherapy with fluoropyrimidine alone is platinum-based chemotherapy, while the standard treatment for early relapse after adjuvant chemotherapy with fluoropyrimidine plus platinum is second-line chemotherapy. To evaluate the efficacy and safety of capecitabine plus cisplatin (XP) treatment for AGC patients who relapse within 6 months after S-1-based therapy, we conducted a multicenter phase II trial (NCT01412294). HER2-negative gastric cancer patients treated with adjuvant chemotherapy including S-1 for more than 12 weeks and relapsed within 6 months were treated with capecitabine 1000 mg/m2bid for 14 days plus cisplatin 80 mg/m2on day 1 of a 3-week cycle. The primary endpoint was PFS; secondary endpoints were OS, time to treatment failure, overall response rate (ORR) and safety. Forty patients (median age 64) were enrolled; of those, 37 (92.5%) received adjuvant S-1 monotherapy. Median PFS was 4.4 months (95% CI 3.6-5.1), which was longer than the 2-month protocol-specified threshold (p < 0.001). Median OS was 13.7 months (95% CI 9.0-17.7) and ORR was 8/30 (26.7%) (95% CI 14.2-44.4). Most common grade ≥ 3 adverse events were neutropenia (23%), anemia (18%), elevated serum creatinine (18%), fatigue (13%), diarrhea (7.5%), and anorexia (7.5%). XP was safe and effective in patients with early relapse after S-1 adjuvant chemotherapy for curatively resected gastric cancers. XP may be a good option for the treatment of patients after early failure after adjuvant S-1. NCT01412294. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 35 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 14% |
| Student > Doctoral Student | 5 | 14% |
| Other | 4 | 11% |
| Student > Master | 3 | 9% |
| Student > Ph. D. Student | 3 | 9% |
| Other | 6 | 17% |
| Unknown | 9 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 34% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Nursing and Health Professions | 2 | 6% |
| Agricultural and Biological Sciences | 2 | 6% |
| Sports and Recreations | 2 | 6% |
| Other | 5 | 14% |
| Unknown | 10 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2018.
All research outputs
#17,932,482
of 23,025,074 outputs
Outputs from Gastric Cancer
#376
of 602 outputs
Outputs of similar age
#240,068
of 330,058 outputs
Outputs of similar age from Gastric Cancer
#7
of 11 outputs
Altmetric has tracked 23,025,074 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 602 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,058 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.